Celera Diagnostics To Focus On Infectious Disease Prior To Cancer, Cardio
This article was originally published in The Gray Sheet
Executive Summary
Celera Diagnostics initially plans to focus on developing diagnostic tests for infectious diseases prior to expanding into cancer and cardiovascular disease
You may also be interested in...
Abbott Gains Access To Celera R&D For Infectious Disease Assays
U.S. clinical lab evaluation of Celera Diagnostics' analyte-specific reagent hepatitis C test by year-end will be among the early milestones of the Applera unit's R&D and marketing agreement with Abbott
Abbott Gains Access To Celera R&D For Infectious Disease Assays
U.S. clinical lab evaluation of Celera Diagnostics' analyte-specific reagent hepatitis C test by year-end will be among the early milestones of the Applera unit's R&D and marketing agreement with Abbott
Celera Diagnostics To Develop Genetic Tests For Hospitals And Labs
Celera Diagnostics will develop genetic tests aimed at the $1 bil. molecular diagnostic market, which is currently growing at a 30% clip, as part of a recently launched business strategy to commercialize products based on analysis of the human genome.